Ensoma

Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As a result, Ensoma’s therapies can be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited.

Ensoma headquartered in United States, North America, operates in the Biotechnology, Life Science, Medical, Therapeutics, Genetics, Oncology sector. The company focuses on Biotechnology and has secured $14.8B in funding across 72 round(s). With a team of 11-50 employees, Ensoma is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - Ensoma, raised $50.0M. Discover more about their projects, partnerships, and impact on our platform.